Benzinga Pro’s Top 5 Stocks To Watch For Thursday, Sept. 2, 2021: GME, BAX, ETWO, FCUV, PSTV
Today's 5 Stock Ideas:
GameStop (GME) - Will report Q2 earnings on Wednesday, Sept. 8 after market close.
Baxter (BAX) - Shares were up 0.5% following news the company will buy Hillrom
Plus Therapeutics Reports Commercial Manufacturing Supply Deal For Its Lead Investigational Drug, No Terms Disclosed
RadioMedix, Inc. is a key manufacturer and supplier of cGMP radiotherapeutics for late-stage clinical trials and commercial production
RadioMedix will produce cGMP drug product for Rhenium-186 NanoLiposome (186RNL) and
Why Is Plus Therapeutics Stock Rising After Data Presentation From Brain Tumor Trial?
Plus Therapeutics Inc's (NASDAQ: PSTV) shares are moving after presenting data from a Phase 1 ReSPECT trial evaluating Rhenium-186 NanoLiposome (186RNL) in recurrent glioblastoma (GBM).
Plus Therapeutics Shares Preclinical Data For Targeted Cancer Radiation Therapy: Highlights
Plus Therapeutics Inc (NASDAQ:PSTV) has presented preclinical data of its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), for leptomeningeal metastases (LM). The…
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today presented
The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among those reporting during the week.